(Q38266397)

1 September 2017

1 reference

title

Dimethyl fumarate for treating relapsing multiple sclerosis (English)

1 reference

1 September 2017

0 references

William Sheremata

1

1 reference

1 September 2017

Andrew D Brown

series ordinal

2

1 reference

1 September 2017

Kottil W Rammohan

series ordinal

3

1 reference

1 September 2017

language of work or name

English

0 references

publication date

8 November 2014

1 reference

Expert Opinion on Drug Safety

1 September 2017

published in

1 reference

1 September 2017

volume

14

1 reference

1 September 2017

issue

1

1 reference

1 September 2017

page(s)

161-170

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.977251

1 September 2017

1 reference

The initiation and prevention of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.977251

Multiple sclerosis: Prospects and promise

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.977251

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.977251

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.977251

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.977251

Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years. Copolymer 1 Multiple Sclerosis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.977251

Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.977251

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.977251

Natalizumab plus interferon beta-1a for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.977251

A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.977251

Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.977251

A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.977251

Randomized trial of oral teriflunomide for relapsing multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.977251

Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.977251

Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.977251

Cerebellar manifestation of PML under fumarate and after efalizumab treatment of psoriasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.977251

Fumaric Acid and its esters: an emerging treatment for multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.977251

Fumaric acid esters, their place in the treatment of psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.977251

Oral fumaric acid esters for the treatment of active multiple sclerosis: an open-label, baseline-controlled pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.977251

Detoxication enzyme inducers modify cytokine production in rat mixed glial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.977251

The Nrf2-antioxidant response element signaling pathway and its activation by oxidative stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.977251

Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.977251

Monomethylfumarate affects polarization of monocyte-derived dendritic cells resulting in down-regulated Th1 lymphocyte responses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.977251

Fumarates improve psoriasis and multiple sclerosis by inducing type II dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.977251

Dimethyl fumarate inhibits dendritic cell maturation via nuclear factor κB (NF-κB) and extracellular signal-regulated kinase 1 and 2 (ERK1/2) and mitogen stress-activated kinase 1 (MSK1) signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.977251

Dimethylfumarate inhibits microglial and astrocytic inflammation by suppressing the synthesis of nitric oxide, IL-1beta, TNF-alpha and IL-6 in an in-vitro model of brain inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.977251

Fumaric acid diesters deprive cultured primary astrocytes rapidly of glutathione.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.977251

Fumaric acid and its esters: an emerging treatment for multiple sclerosis with antioxidative mechanism of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.977251

Hydroxycarboxylic acid receptor 2 mediates dimethyl fumarate's protective effect in EAE.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.977251

Human polyomavirus JC reactivation and pathogenetic mechanisms of progressive multifocal leukoencephalopathy and cancer in the era of monoclonal antibody therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.977251

The Keap1-Nrf2 pathway: Mechanisms of activation and dysregulation in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.977251

Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.977251

Quality of life outcomes with BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: the DEFINE study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.977251

Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.977251

250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.977251

Four new cases of therapy-related acute promyelocytic leukemia after mitoxantrone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.977251

Chemotherapeutics in the treatment of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.977251

Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.977251

Risk of natalizumab-associated progressive multifocal leukoencephalopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.977251

Immunosuppressive therapy reduces axonal damage in progressive multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.977251

Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.977251

10.1517/14740338.2015.977251

21 January 2018

Identifiers

DOI

1 reference

1 September 2017

1 reference